{
    "clinical_study": {
        "@rank": "137904", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal insufficiency (creatinine clearance < 30 mL/min) and not on dialysis.\n10 subjects will receive sofosbuvir 200 mg plus RBV 200 mg for 24 weeks."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants with severe renal insufficiency (creatinine clearance < 30 mL/min) and not on dialysis.\n10 subjects will receive sofosbuvir 400 mg plus RBV 200 mg for 24 weeks"
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "10 subjects will receive sofosbuvir 200 mg plus RBV 200 mg for 24 weeks"
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "10 subjects will receive sofosbuvir 400 mg plus RBV 200 mg for 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety, tolerability and antiviral efficacy of sofosbuvir with\n      ribavirin (RBV) participants with genotype 1 or 3 hepatitis C virus (HCV) infection who have\n      chronic renal insufficiency.\n\n      This study will have 2 parts.\n\n        -  Part 1 will enroll approximately 20 subjects with severe renal insufficiency.\n\n        -  Part 2 will enroll approximately 20 subjects on dialysis following review of safety,\n           efficacy and PK data from Part 1."
        }, 
        "brief_title": "Sofosbuvir Plus Ribavirin in Subjects With HCV Infection and Renal Insufficiency", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "HCV Infection", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic genotype 1 or 3 HCV infection\n\n          -  HCV RNA \u2265 10^4 IU/mL at screening\n\n          -  Screening labs within defined thresholds\n\n          -  Cirrhosis determination at screening\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant or nursing or males who have a pregnant partner\n\n          -  Prior null response to PEG+RBV therapy\n\n          -  Current of prior history of hepatic decompensation\n\n          -  Infection with hepatitis B virus (HBV) or HIV\n\n          -  History of clinically significant illness (including psychiatric or cardiac) or any\n             other medical disorder that may interfere with subject treatment and/or adherence to\n             the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958281", 
            "org_study_id": "GS-US-334-0154", 
            "secondary_id": "2013-002897-30"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Sofosbuvir administered as 100 mg or 400 mg tablet(s) administered orally once daily", 
                "intervention_name": "Sofosbuvir", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Sovaldi\u00ae", 
                    "GS-7977", 
                    "PSI-7977"
                ]
            }, 
            {
                "arm_group_label": [
                    "Cohort 1", 
                    "Cohort 2", 
                    "Cohort 3", 
                    "Cohort 4"
                ], 
                "description": "Ribavirin (RBV) 200 mg tablet administered orally once daily", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33134"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pilar", 
                        "country": "Argentina", 
                        "state": "BA", 
                        "zip": "1629"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria", 
                        "zip": "A-1090"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "D-81241"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "state": "N-H", 
                        "zip": "1105AZ"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ledien", 
                        "country": "Netherlands", 
                        "zip": "2300RC"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gratton", 
                        "country": "New Zealand", 
                        "state": "Auckland", 
                        "zip": "1142"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "8011"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "00927"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Austria", 
                "Germany", 
                "Netherlands", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects With Renal Insufficiency", 
        "overall_contact": {
            "email": "karim.sajwani@gilead.com", 
            "last_name": "Karim Sajwani, MPH, CCRA"
        }, 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Luisa Stamm, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SVR12 is defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, < 25 IU/mL) 12 weeks following the last dose of study drug.", 
                "measure": "Proportion of participants with sustained virologic response 12 weeks after discontinuation of treatment (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Week 12"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24 plus 30 days"
            }, 
            {
                "description": "AUCtau is defined as the concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval)\nCmax is defined as the maximum concentration of drug\nCtau is defined as the observed drug concentration at the end of the dosing interval", 
                "measure": "Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUCtau, Cmax, and Ctau", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AUClast is defined as the concentration of drug from time zero to the last observable concentration\nClast is defined as the last observable concentration of drug\nTmax is defined as the time of Cmax\nTlast is defined as the time of Clast\n\u03bbz is defined as the terminal elimination rate constant\nt1/2 is defined as the estimate of the terminal elimination half-life of the drug", 
                "measure": "Plasma pharmacokinetics (PK) of sofosbuvir and its metabolites, and RBV, including AUClast, Clast, Tmax, Tlast, \u03bbz, and t1/2", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Week 24"
            }, 
            {
                "measure": "Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of treatment (SVR4 and SVR 24)", 
                "safety_issue": "No", 
                "time_frame": "Posttreatment Weeks 4 and 24"
            }, 
            {
                "description": "Virologic failure will be measured by incidence of viral breakthrough and viral relapse.\nViral breakthrough is defined as HCV RNA \u2265 LLOQ after having previously had HCV RNA < LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.\nViral relapse is defined as HCV RNA \u2265 LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.", 
                "measure": "Proportion of participants with virologic failure", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Posttreatment Week 24"
            }
        ], 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}